Ask VialBase
sexual · health

PT-141

Also known as: Bremelanotide, Vyleesi
FDA: FDA-approved as Vyleesi (bremelanotide, 2019) for premenopausal HSDD in women WADA: Not explicitly listed as prohibited

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist — the first and only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi since June 2019. Unlike PDE5 inhibitors (Viagra, Cialis) that work on peripheral blood flow, PT-141 acts centrally on the hypothalamus through MC3R and MC4R to modulate sexual desire and arousal at the neurological level. PT-141 was derived from Melanotan II, an analog of alpha-melanocyte-stimulating hormone (α-MSH). During Melanotan II trials, researchers noticed unexpected pro-sexual effects, leading to focused development of bremelanotide as a stand-alone compound for sexual dysfunction. It works in

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 1,025.21 Da
Half-life ~2.7 hours
CAS number —
Route Subcutaneous · Intranasal subcutaneous preferred
02

Mechanism

Melanocortin receptor agonist (MC3R/MC4R) — acts on hypothalamic neurons to modulate sexual desire and arousal via CNS pathways, not peripheral vasculature

03

Dosing

DOSE RANGE 500–2000 mcg
FREQUENCY As needed (45 min before activity, max 1 dose/24 hrs)
CYCLE LENGTH As needed, max 8 doses/month per FDA labeling

Start at 500mcg to assess tolerance. Can cause nausea and flushing. Do not use with tanning peptides (melanotan). Blood pressure may increase transiently.

04

Research summary

Study Type Year Key Finding
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder — RECONNECT Phase III Trials Phase III randomized double-blind placebo-controlled trial 2019 Bremelanotide 1.75mg SC significantly increased sexual desire vs placebo
Melanocortin receptors in inflammatory disorders: pharmacology and therapeutic relevance Comprehensive review 2025 MC1R-MC5R regulate diverse functions from pigmentation to immune modulation
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer Comprehensive review 2025 Sexual dysfunction is common but underrecognized after breast/gynecologic cancer treatment
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? Expert review / opinion 2026 Argues bremelanotide should be considered for male sexual arousal and desire disorders
An evaluation of the pharmacokinetic and pharmacodynamic effects of bremelanotide administered by intranasally and subcutaneously in healthy male and female volunteers clinical trial 2003 Bremelanotide effective via both intranasal and subcutaneous routes
Bremelanotide for Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial (RECONNECT) RCT 2019 Bremelanotide significantly improved sexual desire in premenopausal women with HSDD
Bremelanotide: new drug for the treatment of hypoactive sexual desire disorder review 2020 Comprehensive review of bremelanotide pharmacology and clinical program
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II clinical trial 2000 Melanotan II (parent compound of PT-141) induced erections in men

Stacks containing PT-141

Feminine Vitality & Libido

PT-141 + Oxytocin + Selank (optional)

Libido Lightning

PT-141 (Bremelanotide) + Oxytocin + DSIP

28-day resets featuring PT-141

05

Sourcing

Current prices

Updated today

10mg

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 20% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Blood Pressure
DURING CYCLE
  • Blood Pressure (30-60 min post-administration)
POST-CYCLE
  • CMP (if frequent use)
Safety & Regulatory Status
FDA STATUS FDA-approved as Vyleesi (bremelanotide, 2019) for premenopausal HSDD in women
WADA STATUS Not explicitly listed as prohibited

Regulatory status for PT-141 may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

References

  1. Kingsberg SA, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder — RECONNECT Phase III Trials. Obstetrics & Gynecology (2019). PMID: 30599891
  2. Various. Melanocortin receptors in inflammatory disorders: pharmacology and therapeutic relevance. Pharmacology Review (2025). PMID: 41002740
  3. Mihulka O, Curran M, Narasimhan RM, Moore JF, Rojas KE. Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer. Journal of Minimally Invasive Gynecology (2025). PMID: 41419078
  4. Pfaus JG, Balon R. Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?. Journal of Clinical Psychopharmacology (2026). PMID: 41960633
  5. Molinoff, P.B., Shadiack, A.M., Earle, D. et al.. An evaluation of the pharmacokinetic and pharmacodynamic effects of bremelanotide administered by intranasally and subcutaneously in healthy male and female volunteers. Journal of Clinical Pharmacology (2003). PMID: 14506269
  6. Kingsberg, S.A., Clayton, A.H., Portman, D. et al.. Bremelanotide for Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial (RECONNECT). Obstetrics and Gynecology (2019). PMID: 30601890
  7. Clayton, A.H., Lucas, J., DeRogatis, L.R. et al.. Bremelanotide: new drug for the treatment of hypoactive sexual desire disorder. Drugs of Today (2020). PMID: 32697022
  8. Wessells, H., Levine, N., Hadley, M.E. et al.. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research (2000). PMID: 10943836